Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 08, 2026 10:00 ET | Source: Dewpoint Therapeutics

Dewpoint Therapeutics Announces TDP-43 Condensate Modulator Development Candidate for Treatment of ALS and Related Neurodegenerative Diseases

First-in-class condensate-modulating small molecule Development Candidate targeting pathogenic TDP-43 condensates in ALS, FTD and traumatic brain injury.
January 06, 2026 10:00 ET | Source: Dewpoint Therapeutics

Dewpoint Therapeutics Launches Initiative to Build Viral Condensate Phenomics Atlas for HPV

Dewpoint Therapeutics launches Gates Foundation-funded initiative to build and share viral condensate phenomics atlas for HPV.
November 17, 2025 10:00 ET | Source: Dewpoint Therapeutics

FDA Grants Fast Track Designation to Dewpoint Therapeutics’ DPTX3186 for the Treatment of Gastric Cancer

U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Dewpoint Therapeutics' DPTX3186
October 29, 2025 10:00 ET | Source: Dewpoint Therapeutics

FDA Grants Orphan Drug Designation to Dewpoint Therapeutics’ DPTX3186 for the Treatment of Gastric Cancer

Dewpoint's DPTX3186 receives FDA Orphan Drug Designation for gastric cancer - the first ever granted to a condensate-modulating therapeutic.